Better Sleep, Better Function: New Study Links Sleep Quality to Clinical Outcomes in Huntington’s Disease
⏱️6 min read | Most people with HD report sleep problems, & new research suggests sleep quality is linked to many aspects of living with the disease. Wearables tracked people with HD for a year & revealed better sleep & strength training might help.
Keeping up with HD research just got easier: Introducing the HDBuzz Trial Tracker
⏱️6 min read | Ever wonder when to expect the next update from a clinical trial for Huntington’s disease? The HDBuzz Trial Tracker puts future updates for HD trials on a clear timeline, with deeper explanations in our articles when you want them.
Vaccines and Neurodegeneration: Lessons for Huntington’s Disease?
⏱️5 min read | Research suggests vaccines may reduce dementia risk by 20%. Infections cause inflammation and toxic byproducts that mitochondria normally clear. In HD, where mitochondria are impaired, vaccination is especially crucial.
UniQure Secures Type A Meeting with FDA: What This Means for AMT-130
⏱️6 min read | UniQure secured a Type A FDA meeting, a high-priority discussion for urgent issues. Within 30 days, both sides will discuss what kind of data package might support the advancement of AMT-130 in the US.
Putting Huntington’s disease medications to the test: results from the Neuro-HD trial
⏱️6 min read | A clinical trial, Neuro-HD, compared 3 common drugs for HD symptoms. The 1 year study found no “best” medication, but clear differences between treatments. The results support a personalised, symptom-by-symptom approach to HD treatment.
HDBuzz Is Officially Independent: What This Means, and Why It Matters
We’re entering a new chapter. HDBuzz is now an independent organisation, strengthening our ability to report clearly, critically, and responsibly on HD research.
EN 
ES 
IT 
DE 
FR 